1. Home
  2. ACET vs YSXT Comparison

ACET vs YSXT Comparison

Compare ACET & YSXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$0.52

Market Cap

93.5M

Sector

Health Care

ML Signal

HOLD

Logo YSX Tech. Co. Ltd Class A Ordinary Shares

YSXT

YSX Tech. Co. Ltd Class A Ordinary Shares

HOLD

Current Price

$1.87

Market Cap

58.6M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACET
YSXT
Founded
1947
2011
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Automotive Aftermarket
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
93.5M
58.6M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
ACET
YSXT
Price
$0.52
$1.87
Analyst Decision
Buy
Analyst Count
4
0
Target Price
$8.50
N/A
AVG Volume (30 Days)
1.9M
588.9K
Earning Date
11-05-2025
07-31-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.18
Revenue
N/A
$71,452,736.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$12.81
Revenue Growth
N/A
22.04
52 Week Low
$0.45
$1.68
52 Week High
$1.12
$9.96

Technical Indicators

Market Signals
Indicator
ACET
YSXT
Relative Strength Index (RSI) 34.97 39.28
Support Level $0.53 $2.02
Resistance Level $0.57 $2.38
Average True Range (ATR) 0.05 0.27
MACD 0.00 -0.01
Stochastic Oscillator 20.77 13.24

Price Performance

Historical Comparison
ACET
YSXT

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

About YSXT YSX Tech. Co. Ltd Class A Ordinary Shares

YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.

Share on Social Networks: